Skip to main content

Sacha Gnjatic, Ph.D., Clinical Team LeaderIcahn School of Medicine at Mount Sinai

I’ve always felt very close to the mission of CRI because of its visionary efforts to promote immunotherapy.
Area of Research: Bladder Cancer, Head and Neck Cancer

As the leader of two separate Clinical Team Grants, Dr. Gnjatic is working with several others to improve the benefits of immunotherapy for patients.

One project, in collaboration with Nina Bhardwaj, M.D., Ph.D., is investigating how checkpoint immunotherapy interacts with chemotherapy as well how mutations influence its effectiveness in advanced bladder cancer. They’ve already uncovered several insights relating to altered immune cell and antibody activity, and plan to use these to guide vaccine development and inform combination treatment approaches.

The other project, in collaboration with Andrew G. Sikora, M.D., Ph.D., Christine Chung, M.D., and Nham Tran, Ph.D., is working to improve the immune-stimulating effects of chemo-radiotherapy (CRT) in HPV-associated head and neck cancer, by targeting the tumor microenvironment (TME). This involves analyzing patient samples before and during CRT, using mouse models of HPV-associated cancer to test different CRT dosing regimens and combinations.

Projects and Grants

The mutation-derived tumor antigen landscape of advanced bladder cancer: A platform to optimize cancer immunotherapy

Icahn School of Medicine at Mount Sinai | Bladder Cancer | 2015

Targeting the tumor immune microenvironment to enhance immune-stimulating effects of chemoradiotherapy

Icahn School of Medicine at Mount Sinai | Head and Neck Cancer | 2015

Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.

Top